Oncoinvent ASA (ONCIN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncoinvent ASA (ONCIN) has a cash flow conversion efficiency ratio of -1.103x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-73.90 Million ≈ $-7.78 Million USD) by net assets (Nkr67.00 Million ≈ $7.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Oncoinvent ASA for the company's overall valuation and market capitalisation.
Oncoinvent ASA - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Oncoinvent ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oncoinvent ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncoinvent ASA ranked by their cash flow conversion efficiency. See Oncoinvent ASA debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Meta Biomed Co. Ltd
KQ:059210
|
0.009x |
|
Lument Finance Trust Inc
NYSE:LFT
|
0.006x |
|
W5 Solutions AB
ST:W5
|
0.074x |
|
Guillemot Corporation S.A.
PA:GUI
|
-0.006x |
|
Savezone I C
KO:067830
|
0.013x |
|
Baoye Group Company Limited
F:BKG
|
0.006x |
|
Doosan Fuel Cell Co. Ltd. Pfd. Series 1
KO:33626K
|
-0.085x |
|
Taiwan Pelican Express Co Ltd
TW:2642
|
0.025x |
Annual Cash Flow Conversion Efficiency for Oncoinvent ASA (2021–2025)
The table below shows the annual cash flow conversion efficiency of Oncoinvent ASA from 2021 to 2025. View ONCIN live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr146.32 Million ≈ $15.40 Million |
Nkr-131.19 Million ≈ $-13.80 Million |
-0.897x | +36.62% |
| 2024-12-31 | Nkr108.33 Million ≈ $11.40 Million |
Nkr-153.24 Million ≈ $-16.13 Million |
-1.415x | -30.56% |
| 2023-12-31 | Nkr127.48 Million ≈ $13.41 Million |
Nkr-138.11 Million ≈ $-14.53 Million |
-1.083x | +66.73% |
| 2022-12-31 | Nkr88.50 Million ≈ $9.31 Million |
Nkr-288.23 Million ≈ $-30.33 Million |
-3.257x | -312.75% |
| 2021-12-31 | Nkr384.43 Million ≈ $40.45 Million |
Nkr-303.34 Million ≈ $-31.92 Million |
-0.789x | -- |
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.